In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children (MEFI_III)
Status:
Completed
Trial end date:
2019-12-19
Target enrollment:
Participant gender:
Summary
This is a classical in vivo clinical trial, following World Health organization's
recommendations, ran as a multisite study within Mozambique trying to assess the efficacy and
safety in 4 sites of the two oral ACTS artemether-lumefantrine (AL) and
Amodiaquine-Artesunate (AQ-AS), first line treatment for malaria in mozambique, for the
treatment of uncomplicated malaria in children aged<5 years.
Phase:
Phase 4
Details
Lead Sponsor:
Centro de Investigacao em Saude de Manhica
Collaborator:
United States Agency for International Development (USAID)
Treatments:
Amodiaquine Artemether Artemether, Lumefantrine Drug Combination Artesunate Lumefantrine